Breadth of Neutralizing Antibody Response to Human Immunodeficiency Virus Type 1 Is Affected by Factors Early in Infection but Does Not Influence Disease Progression

被引:149
作者
Piantadosi, Anne [1 ]
Panteleeff, Dana [1 ]
Blish, Catherine A. [1 ,3 ]
Baeten, Jared M. [2 ,3 ]
Jaoko, Walter [5 ]
McClelland, R. Scott [3 ,4 ,5 ]
Overbaugh, Julie [1 ]
机构
[1] Fred Hutchinson Canc Res Ctr, Div Human Biol, Seattle, WA 98109 USA
[2] Univ Washington, Dept Global Hlth, Seattle, WA 98195 USA
[3] Univ Washington, Dept Med, Seattle, WA 98195 USA
[4] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA
[5] Univ Nairobi, Dept Med Microbiol, Nairobi, Kenya
关键词
LONG-TERM NONPROGRESSORS; CD8(+) T-CELLS; HIV-1-INFECTED SUBJECTS; ANTIRETROVIRAL THERAPY; HIV-1; INFECTION; VIRAL LOAD; VARIANTS; EVOLUTION; ENVELOPE; RISK;
D O I
10.1128/JVI.01149-09
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The determinants of a broad neutralizing antibody (NAb) response and its effect on human immunodeficiency virus type 1 (HIV-1) disease progression are not well defined, partly because most prior studies of a broad NAb response were cross-sectional. We examined correlates of NAb response breadth among 70 HIV-infected, antiretroviral-naive Kenyan women from a longitudinal seroincident cohort. NAb response breadth was measured 5 years after infection against five subtype A viruses and one subtype B virus. Greater NAb response breadth was associated with a higher viral load set point and greater HIV-1 env diversity early in infection. However, greater NAb response breadth was not associated with a delayed time to a CD4(+) T-cell count of <200, antiretroviral therapy, or death. Thus, a broad NAb response results from a high level of antigenic stimulation early in infection, which likely accounts for prior observations that greater NAb response breadth is associated with a higher viral load later in infection.
引用
收藏
页码:10269 / 10274
页数:6
相关论文
共 37 条
[1]   Neutralizing antibodies do not mediate suppression of human immunodeficiency virus type 1 in elite suppressors or selection of plasma virus variants in patients on highly active antiretroviral therapy [J].
Bailey, Justin R. ;
Lassen, Kara G. ;
Yang, Hung-Chih ;
Quinn, Thomas C. ;
Ray, Stuart C. ;
Blankson, Joel N. ;
Siliciano, Robert F. .
JOURNAL OF VIROLOGY, 2006, 80 (10) :4758-4770
[2]   Virological and immunological features of long-term human immunodeficiency virus-infected individuals who have remained asymptomatic compared with those who have progressed to acquired immunodeficiency syndrome [J].
Barker, E ;
Mackewicz, CE ;
Reyes-Terán, G ;
Sato, A ;
Stranford, SA ;
Fujimura, SH ;
Christopherson, C ;
Chang, SY ;
Levy, JA .
BLOOD, 1998, 92 (09) :3105-3114
[3]   HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells [J].
Betts, Michael R. ;
Nason, Martha C. ;
West, Sadie M. ;
De Rosa, Stephen C. ;
Migueles, Stephen A. ;
Abraham, Jonathan ;
Lederman, Michael M. ;
Benito, Jose M. ;
Goepfert, Paul A. ;
Connors, Mark ;
Roederer, Mario ;
Koup, Richard A. .
BLOOD, 2006, 107 (12) :4781-4789
[4]   HIV-1 subtype A envelope variants from early in infection have variable sensitivity to neutralization and to inhibitors of viral entry [J].
Blish, Catherine A. ;
Nedellec, Rebecca ;
Mandaliya, Kishorchandra ;
Mosier, Donald E. ;
Overbaugh, Julie .
AIDS, 2007, 21 (06) :693-702
[5]   Human Immunodeficiency Virus Type 1 Superinfection Occurs despite Relatively Robust Neutralizing Antibody Responses [J].
Blish, Catherine A. ;
Dogan, Ozge C. ;
Derby, Nina R. ;
Nguyen, Minh-An ;
Chohan, Bhavna ;
Richardson, Barbra A. ;
Overbaugh, Julie .
JOURNAL OF VIROLOGY, 2008, 82 (24) :12094-12103
[6]   VIROLOGICAL AND IMMUNOLOGICAL CHARACTERIZATION OF LONG-TERM SURVIVORS OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 INFECTION [J].
CAO, YZ ;
QIN, LM ;
ZHANG, LQ ;
SAFRIT, J ;
HO, DD .
NEW ENGLAND JOURNAL OF MEDICINE, 1995, 332 (04) :201-208
[7]   Neutralizing antibodies are positively associated with CD4+ T-cell counts and T-cell function in long-term AIDS-free infection [J].
Carotenuto, P ;
Looij, D ;
Keldermans, L ;
de Wolf, F ;
Goudsmit, J .
AIDS, 1998, 12 (13) :1591-1600
[8]   A longitudinal study of neutralizing antibodies and disease progression in HIV-1-infected subjects [J].
Cecilia, D ;
Kleeberger, C ;
Muñoz, A ;
Giorgi, JV ;
Zolla-Pazner, S .
JOURNAL OF INFECTIOUS DISEASES, 1999, 179 (06) :1365-1374
[9]   Neutralizing antibody responses against autologous and heterologous viruses in acute versus chronic human immunodeficiency virus (HIV) infection: Evidence for a constraint on the ability of HIV to completely evade neutralizing antibody responses [J].
Decks, Steven G. ;
Schweighardt, Becky ;
Wrin, Terri ;
Galovich, Justin ;
Hoh, Rebecca ;
Sinclair, Elizabeth ;
Hunt, Peter ;
McCune, Joseph M. ;
Martin, Jeffrey N. ;
Petropoulos, Christos J. ;
Hecht, Frederick M. .
JOURNAL OF VIROLOGY, 2006, 80 (12) :6155-6164
[10]   Frequency and Phenotype of Human Immunodeficiency Virus Envelope-Specific B Cells from Patients with Broadly Cross-Neutralizing Antibodies [J].
Doria-Rose, Nicole A. ;
Klein, Rachel M. ;
Manion, Maura M. ;
O'Dell, Sijy ;
Phogat, Adhuna ;
Chakrabarti, Bimal ;
Hallahan, Claire W. ;
Migueles, Stephen A. ;
Wrammert, Jens ;
Ahmed, Rafi ;
Nason, Martha ;
Wyatt, Richard T. ;
Mascola, John R. ;
Connors, Mark .
JOURNAL OF VIROLOGY, 2009, 83 (01) :188-199